| Literature DB >> 19654232 |
Amélie LeBeouf1, Fabrice Mac-Way, Mihai Silviu Utescu, Nadia Chbinou, Pierre Douville, Simon Desmeules, Mohsen Agharazii.
Abstract
BACKGROUND: Abnormal mineral metabolism in chronic kidney disease plays a critical role in vascular calcification and arterial stiffness. The impact of presently used dialysis calcium concentration (D(Ca)) on arterial stiffness and aortic pressure waveform has never been studied. The aim of the present study is to evaluate, in haemodialysis (HD) patients, the impact of acute modification of D(Ca) on arterial stiffness and central pulse wave profile (cPWP). Method. A randomized Latin square cross-over study was used to evaluate the three different concentrations of D(Ca) (1.00, 1.25 and 1.50 mmol/L) during the second HD of the week for 3 consecutive weeks. Subjects returned to their baseline D(Ca) for the following two treatments, allowing for a 7-day washout period between each experimental HD. cPWP, carotido-radial (c-r) and carotido-femoral (c-f) pulse wave velocities (PWV), plasma level of ionized calcium (iCa) and intact parathyroid hormone (PTH) were measured prior to and immediately after each experimental HD session. Data were analysed by the general linear model for repeated measures and by the general linear mixed model.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19654232 PMCID: PMC2781154 DOI: 10.1093/ndt/gfp351
Source DB: PubMed Journal: Nephrol Dial Transplant ISSN: 0931-0509 Impact factor: 5.992
Biochemical and haemodynamic parameters
| DCa (mmol/L) | Repeated measures ANOVA | Linear contrast | |||||
|---|---|---|---|---|---|---|---|
| 1.00 | 1.25 | Ca × HD | Ca | HD | HD × Ca | HD × Ca | |
| iCa (mmol/L) | |||||||
| Pre-HD | 1.17 ± 0.05 | 1.16 ± 0.05 | 1.17 ± 0.06 | <0.001 | 0.09 | <0.001 | <0.001 |
| Post-HD Δ | −0.14 ± 0.04 | −0.02 ± 0.05 | 0.10 ± 0.06 | ||||
| PTH | |||||||
| Pre-HD | 223 ± 170 | 220 ± 150 | 199 ± 145 | <0.001 | 0.68 | <0.001 | <0.001 |
| Post-HD Δ | 237 ± 196 | 49 ± 205 | −104 ± 103 | ||||
| Brachial SBP (mmHg) | |||||||
| Pre-HD | 129 ± 18 | 125 ± 16 | 130 ± 19 | 0.003 | 0.29 | 0.001 | 0.001 |
| Post-HD Δ | −10 ± 19 | −5 ± 15 | 3 ± 14 | ||||
| Brachial DBP (mmHg) | |||||||
| Pre-HD | 79 ± 9 | 79 ± 11 | 79 ± 11 | 0.03 | 0.75 | 0.005 | 0.014 |
| Post-HD Δ | −2 ± 9 | −3 ± 11 | 4 ± 8 | ||||
| Heart rate (b.p.m.) | |||||||
| Pre-HD | 70 ± 12 | 70 ± 17 | 69 ± 10 | 0.20 | 0.74 | 0.46 | 0.28 |
| Post-HD Δ | 2 ± 13 | 0.4 ± 8 | −0.7 ± 7 | ||||
| c-f PWV (m/s) | |||||||
| Pre-HD | 11.6 ± 3.1 | 11 ± 1.8 | 11 ± 2.7 | 0.84 | 0.17 | 0.001 | <0.001 |
| Post-HD Δ | −0.8 ± 1.4 | 0.9 ± 1.9 | 0.8 ± 0.9 | ||||
| c-r PWV (m/s) | |||||||
| Pre-HD | 10.3 ± 1.9 | 9.8 ± 1.6 | 9.8 ± 1.7 | 0.87 | 0.003 | 0.028 | 0.008 |
| Post-HD Δ | 0.16 ± 1.3 | 0.99 ± 1.4 | 1.2 ± 1.4 | ||||
DCa, dialysate calcium concentration; iCa, ionized calcium; PTH, parathyroid hormone; SBP, systolic blood pressure; DBP, diastolic blood pressure; c-f PWV, carotido-femoral pulse wave velocity; c-r PWV, carotido-radial pulse wave velocity.
Central pulse wave profile parameters
| DCa (mmol/L) | Repeated measures ANOVA | Linear contrast | |||||
|---|---|---|---|---|---|---|---|
| 1.00 | 1.25 | 1.50 | Ca | HD | Ca × HD | Ca × HD | |
| SBP (mmHg) | |||||||
| Pre-HD | 120 ± 19 | 115 ± 15 | 120 ± 18 | 0.003 | 0.15 | 0.006 | 0.001 |
| Post-HD Δ | −10 ± 21 | −7 ± 16 | 0.8 ± 15 | ||||
| DBP (mmHg) | |||||||
| Pre-HD | 80 ± 10 | 80 ± 11 | 80 ± 11 | 0.024 | 0.71 | 0.007 | 0.018 |
| Post-HD Δ | −2 ± 9 | −3 ± 11 | 3 ± 8 | ||||
| MBP (mmHg) | |||||||
| Pre-HD | 97 ± 12 | 95 ± 12 | 97 ± 12 | 0.003 | 0.229 | 0.001 | 0.002 |
| Post-HD Δ | −6 ± 11 | −5 ± 13 | 2 ± 10 | ||||
| ESP (mmHg) | |||||||
| Pre-HD | 108 ± 16 | 105 ± 14 | 109 ± 16 | 0.002 | 0.59 | 0.001 | 0.001 |
| Post-HD Δ | −6 ± 17 | −4 ± 15 | 5 ± 13 | ||||
| ED (ms) | |||||||
| Pre-HD | 320 ± 20 | 317 ± 17 | 320 ± 19 | 0.75 | <0.001 | 0.98 | 0.97 |
| Post-HD Δ | −49 ± 37 | −48 ± 31 | −49 ± 27 | ||||
| AIx (%) | |||||||
| Pre-HD | 22 ± 10 | 22 ± 9 | 22 ± 9 | 0.51 | 0.004 | 0.73 | 0.97 |
| Post-HD Δ | −8 ± 14 | −9 ± 11 | −8 ± 11 | ||||
| Tr (ms) | |||||||
| Pre-HD | 143 ± 11 | 145 ± 13 | 144 ± 12 | 0.10 | <0.001 | 0.093 | 0.044 |
| Post-HD Δ | −4 ± 8 | −6 ± 5 | −9 ± 6 | ||||
Pre-HD, pre-haemodialysis value; post-HDΔ, absolute post-dialysis variation of each parameter; DCa, dialysate calcium concentration; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; ESP, end systolic pressure; ED, ejection duration; AIx, heart augmentation index; Tr, time to the start of the reflected wave.
Fig. 1Central pulse wave profile. The central pulse wave profile can be broken into the following parameters: first peak of pressure (P1), second peak of pressure (P2), time at P1 (T1), time at P2 (T2), time of return of the reflection wave (Tr), diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse pressure (PP).
Fig. 2Mean pre- and post-haemodialysis central pressure waveform. Using the mean pressure points at corresponding time points of each patient (n = 18), the group's central pulse wave profile (cPWP) was constructed for each treatment group. The solid line and dotted lines indicate the pre- and post-HD cPWP, respectively. The top, middle and lower panels, respectively, refer to dialysate calcium concentrations of 1.00, 1.25 and 1.50 mmol/L.
Determinants of variation in arterial stiffness and wave reflection
| Estimates of fixed effects | ||
|---|---|---|
| Estimate (95% confidence interval) | ||
| %Δ c-f PWV | ||
| ΔiCa (mmol/L) | 0.566 (0.018–1.114) | 0.043 |
| ΔMBP (mmHg) | 0.002 (−0.002–0.006) | 0.279 |
| %Δ c-r PWV | ||
| ΔiCa (mmol/L) | 0.654 (0.063–1.247) | 0.031 |
| ΔMBP (mmHg) | 0.003 (−0.001–0.007) | 0.131 |
| %Δ Tr | ||
| ΔMBP (mmHg) | −0.001 (−0.002–0.0008) | 0.013 |
| UF (L) | −0.012 (−0.023 to −0.0003) | 0.045 |
| %Δ AIx | ||
| ΔMBP (mmHg) | 0.597 (0.382–0.812) | <0.001 |
| ΔHR (b.p.m.) | −0.420 (−0.660 to −0.179) | 0.001 |
Linear-mixed model for repeated measure.
Covariates in the model include ultrafiltration (UF), changes in the heart rate (ΔHR), ionized calcium (ΔiCa), mean blood pressure (ΔMBP) and parathyroid hormone levels.